Angioplasty.Org
Most Popular Angioplasty Web Site
   
supported by Volcano Corporation
Volcano Reports Record Third Quarter Revenues Company Cites Disposable Revenue Growth, Expanding Installed Base and Release of Favorable Data Around the Use of IVUS

external sites:
Volcano Corporation

November 8, 2007, San Diego, California -- Volcano Corporation (Nasdaq: VOLC), a leading provider of intravascular ultrasound (IVUS) and functional measurement (FM) products designed to enhance the diagnosis and treatment of vascular and structural heart diseases, today reported results for the third quarter and first nine months of fiscal 2007.

For the quarter ended September 30, 2007, Volcano reported record revenues of $31.5 million, a 13 percent increase over revenues of $27.8 million in the third quarter a year ago.

For the third quarter of 2007, the company reported a net loss on a GAAP basis of $652,000, or $0.02 per share, compared with net income of $501,000, or $0.01 per diluted share, in the same period a year ago. Excluding stock-based compensation expense of $2.0 million, the company reported net income of $1.3 million, or $0.03 per diluted share. Excluding stock-based compensation expense of $809,000, the company reported net income of $1.3 million, or $0.04 per diluted share, in the third quarter of 2006. Weighted average basic shares outstanding in the quarter were 38.7 million compared with 33.0 million in the third quarter of 2006. A reconciliation of the company's GAAP to non-GAAP results can be found in today's earnings news release on the company's website at http://www.volcanocorp.com.

Volcano ended the quarter with $92.4 million in cash and cash equivalents and short-term available-for-sale investments. This balance does not include the proceeds from the company's stock offering completed on October 23, 2007, which generated proceeds of approximately $123 million, after deducting underwriting commissions and discounts, but before expenses.

"Our third quarter results represent record revenues for the company and reflect our success at growing sales of our IVUS disposables and expanding our installed base of IVUS consoles. IVUS disposable revenues grew 24 percent globally and 28 percent in the United States year-over-year. Through the first three quarters of 2007, we have placed more IVUS consoles than we did in all of last year. In addition, our year-to-date growth has occurred across all our geographies," said Scott Huennekens, president and chief executive officer of Volcano.

"We believe the growth of our IVUS activity reflects several factors, including the ongoing release of favorable data regarding the value of IVUS in stenting procedures. There were a number of presentations at the recent Transcatheter Cardiovascular Therapeutics (TCT) meeting demonstrating that IVUS can assist interventional cardiologists in providing a more complete diagnosis and prevent stent placement-related complications. In addition, the integration and ease of use provided by our s5 consoles is facilitating adoption of IVUS within the clinical community," Huennekens continued.

"We are further encouraged by recent comments from stent manufacturers suggesting that stenting activity is beginning to rebound and data showing that U.S. PCI volume grew in the third quarter versus the second quarter of this year. We believe that we will benefit from these trends," he added.

During the quarter, the company announced a market alliance with Philips Electronics Japan to promote Volcano's s5i IVUS system with Philips cardiovascular X-ray equipment. The company also said that it expects to have regulatory clearance in the United States for its Revolution rotational catheter on the s5 with Fractional Flow Reserve (FFR) in January 2008, and expects to have regulatory approval in Europe later this year. In Japan, the company has recently launched the Revolution on its IVG IVUS console.

With respect to clinical trial activities, the company said recent highlights included:

  • At TCT, Volcano announced sponsorship of the first major study designed to examine the role of IVUS in accurate stent placement and reduction of clinical events. This sub-study is part of the ADAPT-DES study being administered by the Cardiology Research Foundation, which will explore outcomes for patients with coronary artery disease treated with drug-eluting stents (DES). IVUS will be used in a 3,000 patient sub-study to explore the potential benefits of IVUS-guided PCI to reduce clinical events.
  • Also at TCT, Drs. Gregg Stone and Marty Leon provided data demonstrating that IVUS can reduce thrombosis risk with DES and restonsis and thrombosis risk with bare metal stents. In addition, Dr. Renu Virmani provided data indicating that IVUS can address many of the procedural, device and lesion factors contributing to late stent thrombosis.
  • Baseline data on 700 PROSPECT trial patients was presented at TCT. Key findings demonstrated the value of IVUS in the characterization of major coronary arteries and that IVUS found at least one thin cap fibroatheroma (TCFA) in 28 percent of patients.

For the first nine months of fiscal 2007, revenues were $90.6 million, a 23 percent increase over revenues of $73.5 million in the same period a year ago. On a GAAP basis, the company reported a net loss of $2.8 million, or $0.07 per share, versus a loss of $10.0 million, or $0.60 per share, in the same period a year ago. Included in the results for 2006 is a write-off of $1.2 million, or $0.07 per share, related to deferred debt issuance costs as a result of the company's initial public offering. Excluding stock-based compensation expense of $4.7 million, the company reported net income of $1.9 million, or $0.04 per diluted share, in the first nine months of 2007. Excluding stock-based compensation expense of $2.3 million and the write-off of $1.2 million, the company reported a loss of $6.5 million, or $0.39 per share, in the same period a year ago.

Guidance for 2007
Volcano is providing updated guidance for fiscal 2007. It currently expects that revenues will be in the range of $126-$128 million versus prior guidance for revenues of approximately $125 million. Gross margin for the year is expected to be 59-61 percent versus prior guidance of 60-61 percent. Operating expenses for fiscal 2007 are expected to be 67-68 percent of revenues, as the company intends to continue to accelerate its plan to increase its sales force and to build out its infrastructure to support future growth. This compares with prior guidance for operating expenses of 67-69 percent of revenues. The company expects to report a net loss on a GAAP basis of $0.09-$0.12 per share, compared with prior guidance for a loss of approximately $0.14 per share. Weighted average basic shares outstanding are expected to be approximately 40.0 million shares. This compares with prior guidance for 38.8 million basic shares. Excluding stock-based compensation, Volcano expects to report net income of $0.05-$0.07 per diluted share, assuming approximately 43.4 million weighted average diluted shares outstanding at year end. This compares with prior guidance for net income of approximately $0.04 per diluted share.

Conference Call
The company will hold a conference call at 2 p.m., Pacific Standard Time (5 p.m., Eastern Standard Time) today. The teleconference can be accessed by calling (719) 325-4887, passcode 2329894, or via the company's website at http://www.volcanocorp.com. Please dial in or access the website 10-15 minutes prior to the beginning of the call. A replay of the conference call will be available until November 15 at (719) 457-0820, passcode 2329894 and via the company's website.

Volcano Corporation
Volcano Corporation (NASDAQ: VOLC) offers a broad suite of devices designed to facilitate endovascular procedures, enhance the diagnosis of vascular and structural heart diseases and guide optimal therapies. The company's intravascular ultrasound (IVUS) product line includes ultrasound consoles that can be integrated directly into virtually any modern cath lab. Volcano IVUS offers unique features, including both single-use phased array and rotational IVUS imaging catheters, and advanced functionality options, such as VH(TM) IVUS tissue characterization and ChromaFlo(R). Volcano also provides functional measurement (FM) consoles and single-use pressure and flow guide wires. Currently, more than 2,900 Volcano IVUS and FM systems are installed worldwide, with approximately half of its revenues coming from outside the United States. For more information, visit the company's website at http://www.volcanocorp.com.

Use of Non-GAAP Financial Measure
This news release includes certain non-GAAP financial information as defined by the U.S. Securities and Exchange Commission Regulation G. Pursuant to the requirements of this regulation, a reconciliation of this non-GAAP financial information to our financial statements as prepared under generally accepted accounting principles in the United States (GAAP) is included in this press release. Non-GAAP financial measures provide an indication of our performance before certain charges. Our management believes that in order to properly understand our short-term and long-term financial trends, investors may wish to consider the impact of these charges. These charges result from facts and circumstances that vary in frequency and/or impact on continuing operations. Our management believes that these items should be excluded when comparing our current operating results with those of prior periods as the write-off of deferred debt issuance costs, which results from the repayment of certain debt in connection with our initial public offering, will not impact future operating results, and stock-based compensation is a non-cash expense. In addition, our management uses results of operations before certain charges to evaluate the operational performance of the company and as a basis for strategic planning. Investors should consider these non-GAAP measures in addition to, and not as a substitute for, financial performance measures in accordance with GAAP.

Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this news release regarding Volcano's business that are not historical facts may be considered "forward-looking statements," including statements regarding the company's financial guidance for 2007, regulatory approvals and the impact of obtaining regulatory approvals, market adoption of the company's technology, the impact of clinical and other technical data, the safety and efficacy of the company's products, the success and timing of product development and clinical trial programs, market development and product sales and use. Forward-looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties, which may cause Volcano's results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from the results predicted are detailed in the company's annual report on Form 10-K, quarterly reports on Form 10-Q and other filings made with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Volcano undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.



                             VOLCANO CORPORATION
                    CONDENSED CONSOLIDATED BALANCE SHEETS
                                (in thousands)
                                 (Unaudited)

                                                September 30,      December 31,
                                                    2007              2006
     Assets
     Current assets:
         Cash and cash equivalents                 $49,579           $77,738
         Short-term available-for-sale
          investments                               42,781            17,787
         Accounts receivable, net                   22,801            21,575
         Inventories                                20,687            13,423
         Prepaid expenses and other
          current assets                             3,646             2,208
              Total current assets                 139,494           132,731
     Restricted cash                                   361               352
     Property and equipment, net                    12,552             9,333
     Intangible assets, net                          9,831            11,946
     Other non-current assets                          720               363
                                                  $162,958          $154,725

     Liabilities and Stockholders' Equity
     Current liabilities:
         Accounts payable                          $11,832            $8,209
         Accrued compensation                        7,223             5,993
         Accrued expenses and other
          current liabilities                        5,839             5,292
         Deferred revenues                           4,241             2,675
         Current maturities of
          long-term debt                               322             1,654
              Total current liabilities             29,457            23,823
     Long-term debt                                     90                66
     Deferred license fee                            1,188             1,375
     Other                                             219               279
              Total liabilities                     30,954            25,543
     Stockholders' equity                          132,004           129,182
                                                  $162,958          $154,725



                             VOLCANO CORPORATION
                    CONSOLIDATED STATEMENTS OF OPERATIONS
                    (in thousands, except per share data)
                                 (Unaudited)

                                       Three Months Ended   Nine Months Ended
                                          September 30,        September 30,
                                          2007     2006       2007      2006

    Revenues                            $31,474  $27,782    $90,605   $73,517
    Cost of revenues                     12,285   10,560     35,466    30,248
    Gross profit                         19,189   17,222     55,139    43,269
    Operating expenses:
         Selling, general and
          administrative                 16,005   11,769     44,271    35,027
         Research and development         4,837    3,965     15,241    12,835
         Amortization of intangibles        751      781      2,313     2,332
              Total operating expenses   21,593   16,515     61,825    50,194
     Operating income (loss)             (2,404)     707     (6,686)   (6,925)
     Interest expense                       (32)    (144)      (193)   (3,910)
     Interest and other income, net       2,042      192      4,672     1,072
     Income (loss) before provision
      for income taxes                     (394)     755     (2,207)   (9,763)
     Provision for income taxes             258      254        626       273
     Net income (loss)                    $(652)    $501    $(2,833) $(10,036)
     Net income (loss) per
      share - basic                      $(0.02)   $0.02     $(0.07)   $(0.60)
     Net income (loss) per
      share - diluted                    $(0.02)   $0.01     $(0.07)   $(0.60)
     Weighted-average shares
      outstanding - basic                38,694   32,976     38,368    16,744
     Weighted-average shares
      outstanding - diluted              38,694   36,900     38,368    16,744



                             VOLCANO CORPORATION
            RECONCILIATION OF GAAP AND NON-GAAP OPERATING RESULTS
                    (in thousands, except per share data)
                                 (Unaudited)

                                        Three Months Ended September 30, 2007
                                                       Stock-based
                                                       compensation  Non-GAAP
                                         GAAP results    expense      results

    Revenues                               $31,474          $-       $31,474
    Cost of revenues                        12,285        (181)       12,104
    Gross profit                            19,189         181        19,370
    Operating expenses:
         Selling, general
          and administrative                16,005      (1,437)       14,568
         Research and development            4,837        (359)        4,478
         Amortization of intangibles           751           -           751
              Total operating expenses      21,593      (1,796)       19,797
    Operating loss                          (2,404)      1,977          (427)
    Interest expense                           (32)          -           (32)
    Interest and other income, net           2,042           -         2,042
    Income (loss) before provision for
     income taxes                             (394)      1,977         1,583
    Provision for income taxes                 258           -           258
    Net income (loss)                        $(652)     $1,977        $1,325
    Net income (loss) per share - basic     $(0.02)      $0.05         $0.03
    Net income (loss) per share - diluted   $(0.02)      $0.05         $0.03
    Weighted-average shares
     outstanding - basic                    38,694                    38,694
    Weighted-average shares
     outstanding - diluted                  38,694                    41,710



                                         Three Months Ended September 30, 2006
                                                       Stock-based
                                                       compensation  Non-GAAP
                                         GAAP results    expense      results

    Revenues                               $27,782          $-       $27,782
    Cost of revenues                        10,560        (103)       10,457
    Gross profit                            17,222         103        17,325
    Operating expenses:
         Selling, general
          and administrative                11,769        (573)       11,196
         Research and development            3,965        (133)        3,832
         Amortization of intangibles           781           -           781
              Total operating expenses      16,515        (706)       15,809
    Operating income                           707         809         1,516
    Interest expense                          (144)          -          (144)
    Interest and other income, net             192           -           192
    Income before provision for income
     taxes                                     755         809         1,564
    Provision for income taxes                 254           -           254
    Net income                                $501        $809        $1,310
    Net income per share - basic             $0.02       $0.02         $0.04
    Net income per share - diluted           $0.01       $0.02         $0.04
    Weighted-average shares
     outstanding - basic                    32,976                    32,976
    Weighted-average shares
     outstanding - diluted                  36,900                    36,900



                             VOLCANO CORPORATION
            RECONCILIATION OF GAAP AND NON-GAAP OPERATING RESULTS
                    (in thousands, except per share data)
                                 (Unaudited)

                                     Nine Months Ended September 30, 2007
                                         Stock-based   Write-off of    Non-
                                  GAAP   compensation  deferred debt   GAAP
                                 results    expense   issuance costs  results

    Revenues                     $90,605       $-          $-         $90,605
    Cost of revenues              35,466     (434)          -          35,032
    Gross profit                  55,139      434           -          55,573
    Operating expenses:
         Selling, general
          and administrative      44,271   (3,486)          -          40,785
         Research and
          development             15,241     (783)          -          14,458
         Amortization of
          intangibles              2,313        -           -           2,313
              Total operating
               expenses           61,825   (4,269)          -          57,556
    Operating loss                (6,686)   4,703           -          (1,983)
    Interest expense                (193)       -           -            (193)
    Interest and other
     income, net                   4,672        -           -           4,672
    Income (loss) before
     provision for income taxes   (2,207)   4,703           -           2,496
    Provision for income taxes       626        -           -             626
    Net income (loss)            $(2,833)  $4,703          $-          $1,870
    Net income (loss) per
     share - basic                $(0.07)   $0.12          $-           $0.05
    Net income (loss) per
     share - diluted              $(0.07)   $0.11          $-           $0.04
    Weighted-average shares
     outstanding - basic          38,368                               38,368
    Weighted-average shares
     outstanding - diluted        38,368                               41,739



                                     Nine Months Ended September 30, 2006
                                         Stock-based   Write-off of    Non-
                                  GAAP   compensation  deferred debt   GAAP
                                 results    expense   issuance costs  results

    Revenues                     $73,517       $-          $-         $73,517
    Cost of revenues              30,248     (239)          -          30,009
    Gross profit                  43,269      239           -          43,508
    Operating expenses:
         Selling, general
          and administrative      35,027   (1,680)          -          33,347
         Research and
          development             12,835     (375)          -          12,460
         Amortization of
          intangibles              2,332        -           -           2,332
              Total operating
               expenses           50,194   (2,055)          -          48,139
    Operating loss                (6,925)   2,294           -          (4,631)
    Interest expense              (3,910)       -       1,246          (2,664)
    Interest and other
     income, net                   1,072        -           -           1,072
    Loss before provision
     for income taxes             (9,763)   2,294       1,246          (6,223)
    Provision for income taxes       273        -           -             273
    Net loss                    $(10,036)  $2,294      $1,246         $(6,496)
    Net loss per share - basic
     and diluted                  $(0.60)   $0.14       $0.07          $(0.39)
    Weighted-average shares
     outstanding - basic and
     diluted                      16,744                               16,744


    Use of Non-GAAP Financial Measures
    This press release includes certain non-GAAP financial information as
defined by the U.S. Securities and Exchange Commission Regulation G. Pursuant
to the requirements of this regulation, a reconciliation of this non-GAAP
financial information to our financial statements as prepared under generally
accepted accounting principles in the United States (GAAP) is included in this
press release. Non-GAAP financial measures provide an indication of our
performance before certain charges. Our management believes that in order to
properly understand our short-term and long-term financial trends, investors
may wish to consider the impact of these charges. These charges result from
facts and circumstances that vary in frequency and/or impact on continuing
operations. Our management believes that these items should be excluded when
comparing our current operating results with those of prior periods as the
write-off of deferred debt issuance costs, which resulted from the repayment
of certain debt in connection with our initial public offering, will not
impact future operating results, and stock-based compensation is a non-cash
expense. In addition, our management uses results of operations before certain
charges to evaluate the operational performance of the company and as a basis
for strategic planning. Investors should consider these non-GAAP measures in
addition to, and not as a substitute for, financial performance measures in
accordance with GAAP.



                             VOLCANO CORPORATION
                               REVENUE SUMMARY
                                (in millions)
                                 (Unaudited)


                                                    Q3 '07            Q3 '06
    IVUS Systems:
      United States                                   $3.4              $3.2
      Japan                                            0.5               3.0
      Europe                                           1.5               0.7
      Rest of World                                    0.5               0.9
    Total IVUS Systems                                $5.9              $7.8

    IVUS Disposables:
      United States                                  $10.1              $7.8
      Japan                                            7.5               6.8
      Europe                                           3.0               1.9
      Rest of World                                    0.5               0.5
    Total IVUS Disposables                           $21.1             $17.0

    FM:
      United States                                   $1.4              $1.2
      Japan                                            0.2               0.2
      Europe                                           1.5               0.7
      Rest of World                                    0.2               0.1
    Total FM                                          $3.3              $2.2

    Other                                              1.2               0.8
      Total                                          $31.5             $27.8

Source: Volcano Corporation